Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04987073
Recruiting Not applicable

Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency

NCT04987073 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Caen
Phase
Not applicable
Started
2022-07-17
Last updated
2025-07-25

Condition(s) studied

Idiopathic Infantile Hypercalcemia - Severe Form

Investigational drug(s) / intervention(s)

skin biopsy

skin biopsy: A skin biopsy to cultivate fibroblasts.

Study summary

Preclinical evaluation of a vitamin D analog for the treatment of vitamin D 24-hydroxylase using fibroblast from patients with CYP24A1 mutation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * biallelic mutation in CYP24A1 * consent Exclusion Criteria: * none

Primary outcome measure(s)

  • Effects of the analog on vitamin D induced genes' expression — 3 years
    RNA quantification of genes induced by vitamin D in presence of analog in patients' fibroblast

Trial sites (1)

FacilityCityRegionStatus
Arnaud Molin Caen Normandy Recruiting

More University Hospital, Caen trials in France

NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER Recruiting
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study Active, not recruiting
Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs Recruiting
Longitudinal Monitoring of Head Impacts in Elite Junior Ice Hockey Active, not recruiting
An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04987073 on ClinicalTrials.gov ↗ ← All trials in France